Arcturus Therapeutics Holdings Inc (ARCT)

Form 8-K - Current report

Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights Arcturus Therapeutics Holdings Inc...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Initiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of...

Form DEF 14A - Other definitive proxy statements

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in BiotechBioMedWire Editorial...

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]